Compounds > spironolactone
Page last updated: 2024-11-07

spironolactone and Atrial Fibrillation

spironolactone has been researched along with Atrial Fibrillation in 62 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Research Excerpts

ExcerptRelevanceReference
"While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF."9.51Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022)
"At present, the question of whether radiofrequency ablation (RFA) combined with spironolactone can reduce the levels of plasma angiotensin II (AngII) and aldosterone (ALD) in patients with atrial fibrillation (AF) and reduce the recurrence of AF has not been reported."9.41Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study. ( Chen, J; Chen, L; Chen, Q; Chen, X; Li, J; Sun, X; Wang, W; Xu, Z; Zhang, F, 2021)
"This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)."9.30Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019)
"Eplerenone is reported to reduce the development of atrial fibrillation (AF)."9.24Eplerenone might affect atrial fibrosis in patients with hypertension. ( Fukunami, M; Furukawa, Y; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Morita, T; Okuyama, Y; Sakata, Y; Tamaki, S; Yamada, T, 2017)
"The single-centre IMproved exercise tolerance In heart failure With PReserved Ejection fraction by Spironolactone On myocardial fibrosiS In Atrial Fibrillation (IMPRESS-AF) trial aims to establish whether treatment with spironolactone as compared with placebo improves exercise tolerance (cardiopulmonary exercise testing), quality of life and diastolic function in patients with permanent atrial fibrillation."9.22IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. ( Calvert, M; Fisher, J; Gill, PS; Haynes, R; Kirchhof, P; Lip, GY; Shantsila, E, 2016)
"Spironolactone could reduce the levels of serum aldosterone and PICP in patients with atrial fibrillation, so as to reduce the atrial fibrosis and delay the occurrence and development of atrial fibrillation."9.19The role of spironolactone in the metabolism of serum type I collagen in elderly patients with atrial fibrillation. ( Jin, TR; Shao, J; Wang, J; Zhang, LX; Zhang, SH, 2014)
"In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset AFF."9.16Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. ( Krum, H; McMurray, JJ; Pitt, B; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2012)
"The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown."7.85Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling. ( Berenfeld, O; Ennis, SR; Guerrero-Serna, G; Jalife, J; Kaur, K; Ponce-Balbuena, D; Ramirez, RJ; Ramos-Mondragón, R; Salvador-Montañés, O; Takemoto, Y, 2017)
"Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear."7.83Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy. ( Chen, PC; Chiang, FT; Chung, YW; Hwang, JJ; Juang, JM; Lai, LP; Lin, JL; Lin, LY; Tsai, CT; Wang, YC; Wu, CK; Yang, YH; Yu, CC, 2016)
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors."7.79[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013)
"Several studies have demonstrated a relation between the rennin-angiotensin-aldosterone system and atrial fibrillation (AF), but there are no reports on the effect of eplerenone, a selective aldosterone blocker, on the prevention of AF recurrence after radiofrequency catheter ablation (RFCA)."7.79Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. ( Aonuma, K; Igarashi, M; Ito, Y; Kaneshiro, T; Kunugita, F; Kuroki, K; Machino, T; Murakoshi, N; Naruse, Y; Sato, A; Sekiguchi, Y; Tada, H; Xu, D; Yamasaki, H; Yoshida, K, 2013)
"Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents."7.77Effect of spironolactone on patients with atrial fibrillation and structural heart disease. ( deLemos, JA; Dimas, V; Hill, JA; Naseem, RH; Reisch, J; Williams, RS, 2011)
"To investigate the effects of perindopril and spirolactone on plasma aldosterone (Ald) and left atrial remodeling and function in a canine model of atrial fibrillation (AF)."7.75[Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation]. ( DU, X; Lei, T; Liu, XH; Liu, XP; Luo, TY; Shi, JH; Wang, HY, 2009)
"Spironolactone contributes to AF prevention in congestive heart failure dogs induced by chronic rapid ventricular pacing, which is related to atrial fibrosis reduction and independent of hemadynamics."7.74Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. ( Cao, Y; Dong, G; Han, W; Huo, H; Li, WM; Wang, BC; Wei, N; Xiu, CH; Yang, SS; Zhou, G; Zhou, HY, 2008)
"Three months after myocardial infarction (MI), rats were treated for 1 month with spironolactone, lisinopril, or atenolol alone or in combination."7.73Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005)
"Aldosterone is a key component in this process."6.90Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial. ( Alexandre, J; Allouche, S; Beygui, F; Buklas, D; Chequel, M; Cholley, B; Dolladille, C; Fellahi, JL; Fischer, MO; Legallois, D; Milliez, P; Ollitrault, P; Parienti, JJ; Rozec, B; Saplacan, V, 2019)
"We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity."6.87Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. ( Chen, S; Hoye, NA; Kiuchi, MG; Pürerfellner, H, 2018)
"While median time to cardiac death in the spironolactone group was not statistically significantly different than that in the placebo group, adding spironolactone to conventional therapy resulted in reduced occurrence of AF."5.51Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy. ( Chambers, H; Fonfara, S; Laskary, A; O'Sullivan, ML, 2022)
"Hyperaldosteronism is associated with an increased prevalence of atrial fibrillation (AF)."5.43Increased aldosterone-dependent Kv1.5 recycling predisposes to pacing-induced atrial fibrillation in Kcne3-/- mice. ( Buschmeyer, B; Koehncke, C; Lisewski, U; Pieske, B; Roepke, TK; Wilck, N, 2016)
" Treatment with spironolactone did not affect the biomarker of fibrosis Gal-3 in AF patients."5.41Galectin-3 in patients with atrial fibrillation and restored sinus rhythm. ( Angelov, A; Bocheva, Y; Chervenkov, T; Kisheva, A; Yotov, Y, 2021)
"At present, the question of whether radiofrequency ablation (RFA) combined with spironolactone can reduce the levels of plasma angiotensin II (AngII) and aldosterone (ALD) in patients with atrial fibrillation (AF) and reduce the recurrence of AF has not been reported."5.41Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study. ( Chen, J; Chen, L; Chen, Q; Chen, X; Li, J; Sun, X; Wang, W; Xu, Z; Zhang, F, 2021)
"Aldosterone treatment resulted in hypertrophy as indicated by an increased ratio of heart weight/tibia length and doubled the time until the AF converted spontaneously into sinus rhythm (85."5.38Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. ( Brandt, MC; Dartsch, T; Halbach, M; Hescheler, J; Hoppe, UC; Lammers, C; Müller-Ehmsen, J; Ockenpoehler, S; Peinkofer, G; Reuter, H; Rottländer, D; Schneider, T; Weiergraeber, M; Zobel, C, 2012)
"Spironolactone treatment reversed the increased expression of caspase-3, bax, calpain I and MMP-9 and the decreased level of Bcl-2, calpastatin and TIMP-1, induced by chronic atrial pacing."5.36Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Gong, Y; Li, J; Li, W; Li, Y; Shan, H; Yang, B; Zhao, J, 2010)
"This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)."5.30Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019)
"This study assessed the relationship between atrial fibrillation (AF) and outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial, to evaluate whether AF modified the treatment response to spironolactone and whether spironolactone influenced post-randomization AF."5.27Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. ( Anand, IS; Cikes, M; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Saksena, S; Shah, AM; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018)
"Eplerenone is reported to reduce the development of atrial fibrillation (AF)."5.24Eplerenone might affect atrial fibrosis in patients with hypertension. ( Fukunami, M; Furukawa, Y; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Morita, T; Okuyama, Y; Sakata, Y; Tamaki, S; Yamada, T, 2017)
"The single-centre IMproved exercise tolerance In heart failure With PReserved Ejection fraction by Spironolactone On myocardial fibrosiS In Atrial Fibrillation (IMPRESS-AF) trial aims to establish whether treatment with spironolactone as compared with placebo improves exercise tolerance (cardiopulmonary exercise testing), quality of life and diastolic function in patients with permanent atrial fibrillation."5.22IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. ( Calvert, M; Fisher, J; Gill, PS; Haynes, R; Kirchhof, P; Lip, GY; Shantsila, E, 2016)
"Spironolactone could reduce the levels of serum aldosterone and PICP in patients with atrial fibrillation, so as to reduce the atrial fibrosis and delay the occurrence and development of atrial fibrillation."5.19The role of spironolactone in the metabolism of serum type I collagen in elderly patients with atrial fibrillation. ( Jin, TR; Shao, J; Wang, J; Zhang, LX; Zhang, SH, 2014)
"In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset AFF."5.16Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. ( Krum, H; McMurray, JJ; Pitt, B; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F, 2012)
"The aldosterone inhibitor eplerenone (EPL) has been shown to reduce the incidence of atrial fibrillation (AF) in patients with systolic heart failure, but the mechanism is unknown."3.85Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling. ( Berenfeld, O; Ennis, SR; Guerrero-Serna, G; Jalife, J; Kaur, K; Ponce-Balbuena, D; Ramirez, RJ; Ramos-Mondragón, R; Salvador-Montañés, O; Takemoto, Y, 2017)
"Whether the spironolactone treatment remains effective for the prevention of atrial fibrillation (AF) in dialysis patients is unclear."3.83Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy. ( Chen, PC; Chiang, FT; Chung, YW; Hwang, JJ; Juang, JM; Lai, LP; Lin, JL; Lin, LY; Tsai, CT; Wang, YC; Wu, CK; Yang, YH; Yu, CC, 2016)
" Recently, eplerenone (EPL) has been found to reduce the incidence of nonsurgical AF when added to guideline-recommended therapy in patients with systolic heart failure."3.81Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study. ( Aidonidis, I; Hatziefthimiou, A; Simopoulos, V; Skoularigis, I; Tagarakis, G; Trantou, V; Triposkiadis, F; Tsilimingas, N, 2015)
"It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors."3.79[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013)
"Several studies have demonstrated a relation between the rennin-angiotensin-aldosterone system and atrial fibrillation (AF), but there are no reports on the effect of eplerenone, a selective aldosterone blocker, on the prevention of AF recurrence after radiofrequency catheter ablation (RFCA)."3.79Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. ( Aonuma, K; Igarashi, M; Ito, Y; Kaneshiro, T; Kunugita, F; Kuroki, K; Machino, T; Murakoshi, N; Naruse, Y; Sato, A; Sekiguchi, Y; Tada, H; Xu, D; Yamasaki, H; Yoshida, K, 2013)
"Spironolactone therapy in patients with atrial fibrillation provides additional clinical benefits in addition to the current conventional pharmacological agents."3.77Effect of spironolactone on patients with atrial fibrillation and structural heart disease. ( deLemos, JA; Dimas, V; Hill, JA; Naseem, RH; Reisch, J; Williams, RS, 2011)
" Hypothesising that selective MR antagonism might also influence atrial ion currents (L-type calcium current [I (Ca,L)], transient outward potassium current [I (to)], sustained outward potassium current [I (sus)]) and their tachycardia-induced remodelling, the effects of an eplerenone treatment were studied in a rabbit model."3.76Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. ( Bentz, K; Eick, C; Kettering, K; Konior, A; Laszlo, R; Schreieck, J; Schreiner, B, 2010)
"To investigate the effects of perindopril and spirolactone on plasma aldosterone (Ald) and left atrial remodeling and function in a canine model of atrial fibrillation (AF)."3.75[Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation]. ( DU, X; Lei, T; Liu, XH; Liu, XP; Luo, TY; Shi, JH; Wang, HY, 2009)
"Spironolactone contributes to AF prevention in congestive heart failure dogs induced by chronic rapid ventricular pacing, which is related to atrial fibrosis reduction and independent of hemadynamics."3.74Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. ( Cao, Y; Dong, G; Han, W; Huo, H; Li, WM; Wang, BC; Wei, N; Xiu, CH; Yang, SS; Zhou, G; Zhou, HY, 2008)
"Three months after myocardial infarction (MI), rats were treated for 1 month with spironolactone, lisinopril, or atenolol alone or in combination."3.73Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. ( Beaufils, P; Deangelis, N; Delcayre, C; Hatem, SN; Leenhardt, A; Milliez, P; Robidel, E; Rucker-Martin, C; Vicaut, E, 2005)
"We describe a patient with cirrhotic liver disease and atrial fibrillation who was treated with spironolactone and digoxin."3.69A new interference in some digoxin assays: anti-murine heterophilic antibodies. ( Ghali, JK; Graves, SW; Liendo, C, 1996)
"Aldosterone is a key component in this process."2.90Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial. ( Alexandre, J; Allouche, S; Beygui, F; Buklas, D; Chequel, M; Cholley, B; Dolladille, C; Fellahi, JL; Fischer, MO; Legallois, D; Milliez, P; Ollitrault, P; Parienti, JJ; Rozec, B; Saplacan, V, 2019)
"We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity."2.87Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. ( Chen, S; Hoye, NA; Kiuchi, MG; Pürerfellner, H, 2018)
"Spironolactone use was also associated with a shorter duration of mechanical ventilation after surgery."2.77Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. ( Ball, SK; Billings, FT; Body, SC; Brown, NJ; Byrne, JG; Greelish, JP; Hoff, SJ; Mishra, V; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2012)
"Aldosterone has been implicated in atrial remodelling representing a potential target for upstream therapies."2.53Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. ( Korantzopoulos, P; Letsas, KP; Li, G; Liu, T; Shao, Q; Zhang, Z, 2016)
"Spironolactone has been shown to exert positive effects in human patients with heart failure; however, the mechanisms and effects in human atrial fibrosis and AF remain undetermined."2.46Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. ( Lyon, RC; Pellman, J; Sheikh, F, 2010)
"Hyperaldosteronism is associated with an increased prevalence of atrial fibrillation (AF)."1.43Increased aldosterone-dependent Kv1.5 recycling predisposes to pacing-induced atrial fibrillation in Kcne3-/- mice. ( Buschmeyer, B; Koehncke, C; Lisewski, U; Pieske, B; Roepke, TK; Wilck, N, 2016)
"Aldosterone treatment resulted in hypertrophy as indicated by an increased ratio of heart weight/tibia length and doubled the time until the AF converted spontaneously into sinus rhythm (85."1.38Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. ( Brandt, MC; Dartsch, T; Halbach, M; Hescheler, J; Hoppe, UC; Lammers, C; Müller-Ehmsen, J; Ockenpoehler, S; Peinkofer, G; Reuter, H; Rottländer, D; Schneider, T; Weiergraeber, M; Zobel, C, 2012)
"Hypertension is well known to increase atrial fibrillation (AF) and the development of AF is associated with atrial chamber remodeling."1.37Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. ( Aizawa, Y; Chinushi, M; Ding, L; Hanawa, H; Hoyano, M; Ito, M; Kimura, S; Kodama, M; Obata, H; Tomita, M, 2011)
"Spironolactone treatment reversed the increased expression of caspase-3, bax, calpain I and MMP-9 and the decreased level of Bcl-2, calpastatin and TIMP-1, induced by chronic atrial pacing."1.36Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. ( Gong, Y; Li, J; Li, W; Li, Y; Shan, H; Yang, B; Zhao, J, 2010)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-19904 (6.45)18.7374
1990's2 (3.23)18.2507
2000's8 (12.90)29.6817
2010's40 (64.52)24.3611
2020's8 (12.90)2.80

Authors

AuthorsStudies
Ho, JE1
Naccarelli, GV1
Filippone, EJ1
Foy, A1
Wang, W1
Chen, Q1
Zhang, F1
Chen, X1
Xu, Z1
Sun, X1
Li, J2
Chen, L1
Chen, J1
Lou, YM1
Zheng, ZL1
Xie, LY1
Lian, JF1
Shen, WJ1
Zhou, JQ1
Shao, GF1
Hu, DX1
Kisheva, A1
Yotov, Y1
Chervenkov, T1
Angelov, A1
Bocheva, Y1
Laskary, A1
Fonfara, S1
Chambers, H1
O'Sullivan, ML1
O'Neal, WT2
Sandesara, P2
Patel, N1
Venkatesh, S2
Samman-Tahhan, A2
Hammadah, M2
Kelli, HM2
Soliman, EZ2
Kawasaki, M1
Yamada, T1
Okuyama, Y1
Morita, T1
Furukawa, Y1
Tamaki, S1
Iwasaki, Y1
Kikuchi, A1
Sakata, Y1
Fukunami, M1
Ferreira, JP1
Girerd, N1
Zannad, F2
Sanders, P1
Elliott, AD1
Linz, D1
Takemoto, Y1
Ramirez, RJ1
Kaur, K1
Salvador-Montañés, O1
Ponce-Balbuena, D1
Ramos-Mondragón, R1
Ennis, SR1
Guerrero-Serna, G1
Berenfeld, O1
Jalife, J1
Kiuchi, MG1
Chen, S1
Hoye, NA1
Pürerfellner, H1
Calhoun, DA1
Franken, PR1
Woltersdorf, R1
Cikes, M1
Claggett, B1
Shah, AM1
Desai, AS1
Lewis, EF1
Shah, SJ1
Anand, IS1
O'Meara, E1
Rouleau, JL1
Sweitzer, NK2
Fang, JC1
Saksena, S1
Pitt, B2
Pfeffer, MA1
Solomon, SD1
DeVore, AD1
Piccini, JP1
Merrill, M1
Lindenfeld, J1
Kao, DP1
Alexandre, J1
Ollitrault, P1
Fischer, MO1
Fellahi, JL1
Rozec, B1
Cholley, B1
Dolladille, C1
Chequel, M1
Allouche, S1
Legallois, D1
Saplacan, V1
Buklas, D1
Beygui, F1
Parienti, JJ1
Milliez, P2
Neefs, J1
van den Berg, NWE1
Krul, SPJ1
Boekholdt, SM1
de Groot, JR1
Andreev, DA1
Gappoeva, ZK1
Sychev, DA1
Giliarov, MIu1
Lavall, D1
Selzer, C1
Schuster, P1
Lenski, M1
Adam, O1
Schäfers, HJ1
Böhm, M1
Laufs, U1
Simopoulos, V1
Tagarakis, G1
Hatziefthimiou, A1
Skoularigis, I1
Triposkiadis, F1
Trantou, V1
Tsilimingas, N1
Aidonidis, I1
Zhang, SH1
Wang, J1
Jin, TR1
Zhang, LX1
Shao, J1
Moret, M1
Darbellay, P1
Lebowitz, D1
Alves, C1
Sabeh, N1
Carballo, S1
Chung, YW1
Yang, YH1
Wu, CK1
Yu, CC1
Juang, JM1
Wang, YC1
Tsai, CT1
Lin, LY1
Lai, LP1
Hwang, JJ1
Chiang, FT1
Chen, PC1
Lin, JL1
Liu, T1
Korantzopoulos, P1
Shao, Q1
Zhang, Z1
Letsas, KP1
Li, G1
Lisewski, U1
Koehncke, C1
Wilck, N1
Buschmeyer, B1
Pieske, B1
Roepke, TK1
Shantsila, E1
Haynes, R1
Calvert, M1
Fisher, J1
Kirchhof, P1
Gill, PS1
Lip, GY1
Dabrowski, R4
Sosnowski, C3
Michalak, E1
Szwed, H4
Pellman, J1
Lyon, RC1
Sheikh, F1
Luo, TY1
Liu, XH1
DU, X1
Liu, XP1
Lei, T1
Wang, HY1
Shi, JH1
Zhao, J1
Li, W1
Li, Y1
Shan, H1
Gong, Y1
Yang, B1
Jolobe, OM3
Ozaydin, M1
Varol, E1
Türker, Y1
Peker, O1
Erdoğan, D1
Doğan, A1
Ibrişim, E1
Lendeckel, U1
Dobrev, D1
Goette, A1
Laszlo, R1
Bentz, K1
Konior, A1
Eick, C1
Schreiner, B1
Kettering, K1
Schreieck, J1
Borowiec, A2
Smolis-Bak, E1
Kowalik, I2
Kraska, A1
Kazimierska, B1
Wozniak, J1
Zareba, W1
Kimura, S1
Ito, M1
Tomita, M1
Hoyano, M1
Obata, H1
Ding, L1
Chinushi, M1
Hanawa, H1
Kodama, M1
Aizawa, Y1
Williams, RS1
deLemos, JA1
Dimas, V1
Reisch, J1
Hill, JA1
Naseem, RH1
Swedberg, K1
McMurray, JJ1
Krum, H1
van Veldhuisen, DJ1
Shi, H1
Vincent, J1
Lammers, C1
Dartsch, T1
Brandt, MC1
Rottländer, D1
Halbach, M1
Peinkofer, G1
Ockenpoehler, S1
Weiergraeber, M1
Schneider, T1
Reuter, H1
Müller-Ehmsen, J1
Hescheler, J1
Hoppe, UC1
Zobel, C1
Pretorius, M1
Murray, KT1
Yu, C1
Byrne, JG1
Billings, FT1
Petracek, MR1
Greelish, JP1
Hoff, SJ1
Ball, SK1
Mishra, V1
Body, SC1
Brown, NJ1
Smolis Bąk, E1
Stafford-Smith, M1
Bang, CN1
Greve, AM1
Wachtell, K1
Kober, L1
Ito, Y1
Yamasaki, H1
Naruse, Y1
Yoshida, K1
Kaneshiro, T1
Murakoshi, N1
Igarashi, M1
Kuroki, K1
Machino, T1
Xu, D1
Kunugita, F1
Sekiguchi, Y1
Sato, A1
Tada, H1
Aonuma, K1
Williams, ES1
Miller, JM1
Deangelis, N1
Rucker-Martin, C1
Leenhardt, A1
Vicaut, E1
Robidel, E1
Beaufils, P1
Delcayre, C1
Hatem, SN1
Nattel, S1
Nishimura, H1
Yang, SS1
Han, W1
Zhou, HY1
Dong, G1
Wang, BC1
Huo, H1
Wei, N1
Cao, Y1
Zhou, G1
Xiu, CH1
Li, WM1
Padrón, FA1
Armijo, JA1
Liendo, C1
Ghali, JK1
Graves, SW1
Kulbertus, H1
Ohmae, M1
Nohara, Y1
Takayasu, M1
Saimyoji, H1
Seriu, Y1
Olesen, KH1
Valentin, N1
Thind, GS1
Blakemore, WS1
Zinsser, HF1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure[NCT04160000]Phase 4360 participants (Anticipated)Interventional2020-07-26Recruiting
Randomized Clinical Trial of Radiofrequency Ablation for Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction for Reduced Healthcare Utilization[NCT04327596]2 participants (Actual)Interventional2021-01-25Terminated (stopped due to lack of enrollment)
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302]Phase 33,445 participants (Actual)Interventional2006-08-31Completed
Spironolactone and Perioperative Atrial Fibrillation Occurrence in Cardiac Surgery Patients: a Multicenter Randomized, Double-blind Study. The ALDOCURE Trial[NCT03551548]Phase 31,500 participants (Anticipated)Interventional2019-02-26Recruiting
Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation[NCT02673463]Phase 4250 participants (Anticipated)Interventional2015-01-31Active, not recruiting
Pilot Non Randomised Controlled Trial of Short Term Spironolactone Use for Prevention of Acute Kidney Injury After Cardiac Surgery[NCT02417896]150 participants (Anticipated)Interventional2013-04-30Recruiting
RAAS, Inflammation, and Post-operative AF[NCT00141778]Phase 2/Phase 3455 participants (Actual)Interventional2005-04-30Completed
Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658]Phase 390 participants (Anticipated)Interventional2017-08-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Aborted Cardiac Arrest

First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo0.09
Spironolactone0.05

All-cause Mortality

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo4.6
Spironolactone4.2

Cardiovascular Mortality

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo3.1
Spironolactone2.8

Cardiovascular-related Hospitalization

Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo6.2
Spironolactone5.5

Chloride

Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmEq/L (Least Squares Mean)
Placebo102.33
Spironolactone102.26

Composite Outcome of Cardiovascular Mortality or Cardiovascular-related Hospitalization (i.e., Hospitalization for Myocardial Infarction(MI), Stroke, or the Management of Heart Failure), Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo7.8
Spironolactone7.2

Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo6.6
Spironolactone5.9

Composite Outcome of Sudden Death or Aborted Cardiac Arrest, Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.0

Composite Outcome of Sudden Death, Aborted Cardiac Arrest, or Hospitalization for the Management of Ventricular Tachycardia, Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.0

Depression Symptoms, as Measured by Patient Health Questionnaire.

"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo5.6
Spironolactone5.1

Deterioration of Renal Function

First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo2.2
Spironolactone3.2

Development of Atrial Fibrillation, Among Subjects Without a History of Atrial Fibrillation at Baseline.

First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.4
Spironolactone1.4

Estimated Glomerular Filtration Rate (GFR)

Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmL/min/1.73m2 (Least Squares Mean)
Placebo67.50
Spironolactone65.20

Hospitalization for Any Reason

First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo20.0
Spironolactone18.8

Hospitalization for the Management of Heart Failure

First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo4.6
Spironolactone3.8

Myocardial Infarction

First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.2

New Onset Diabetes Mellitus, Among Subjects Without a History of Diabetes Mellitus at Baseline.

First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo0.7
Spironolactone0.7

Potassium

Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmEq/L (Least Squares Mean)
Placebo4.32
Spironolactone4.49

Quality of Life, as Measured by McMaster Overall Treatment Evaluation Questionnaire.

"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo1.2
Spironolactone1.2

Quality of Life, as Measured by the EuroQOL Visual Analog Scale.

"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo65.9
Spironolactone66.4

Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire.

"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo63.1
Spironolactone64.4

Serum Creatinine

Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionmg/dL (Least Squares Mean)
Placebo1.11
Spironolactone1.17

Sodium

Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmEq/L (Least Squares Mean)
Placebo140.95
Spironolactone140.33

Stroke

First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.0

Total Hospitalizations (Including Repeat Hospitalizations) for the Management of Heart Failure

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo8.3
Spironolactone6.8

Acute Renal Failure

Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.

Interventionpercentage of patients (Number)
Placebo5.4
Ramipril0.7
Spironolactone0.7

Death

The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge

Interventionpercentage of patients (Number)
Placebo1.4
Ramipril2.0
Spironolactone0

Hypokalemia

Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.

Interventionpercentage of patients (Number)
Placebo11.6
Ramipril13.8
Spironolactone6.8

Hypotension

Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.

Interventionpercentage of patients (Number)
Placebo5.4
Ramipril10.6
Spironolactone10.2

Length of Hospital Stay (Days)

(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge

Interventiondays (Mean)
Placebo6.8
Ramipril5.7
Spironolactone5.8

Postoperative Atrial Fibrillation

The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital

Interventionpercentage of patients (Number)
Placebo27.2
Ramipril27.8
Spironolactone25.9

Stroke

Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.

Interventionpercentage of patients (Number)
Placebo2.7
Ramipril1.3
Spironolactone2.0

Time to Tracheal Extubation

It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation

Interventionminutes (Mean)
Placebo1091.3
Ramipril970.1
Spironolactone576.4

Perioperative C-reactive Protein (CRP) Concentrations

C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period

,,
Interventionug/mL (Mean)
Initiation of surgeryPostoperative day 1Postoperative day 2Postoperative day 3Postoperative day 4
Placebo4.151.4134.8128.394.1
Ramipril4.349.9131.0164.8105.2
Spironolactone3.964.3127.8189.4126.5

Perioperative Interleukin(IL)-6 Concentrations

Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period

,,
Interventionpg/ml (Mean)
Initiation of surgery30min intraop60min intraopPostopPostoperative day 1Postoperative day 2
Placebo4.712.015.6130.0119.0100.3
Ramipril4.620.528.8202.1171.095.5
Spironolactone6.611.317.4145.7164.9109.6

Perioperative Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations

Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period

,,
Interventionng/mL (Mean)
Initiation of surgery30min intraop60min intraopPostopPostoperative day 1Postoperative day 2
Placebo19.619.221.036.455.228.1
Ramipril16.219.722.038.947.925.7
Spironolactone17.317.320.134.048.931.0

Reviews

4 reviews available for spironolactone and Atrial Fibrillation

ArticleYear
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2016, Volume: 18, Issue:5

    Topics: Aldosterone; Atrial Fibrillation; Cardiac Surgical Procedures; Eplerenone; Heart Failure; Humans; Mi

2016
Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation.
    Journal of molecular and cellular cardiology, 2010, Volume: 48, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Extracellular Matrix; Fibrosi

2010
Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation.
    Cardiology journal, 2012, Volume: 19, Issue:3

    Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Eplerenone; Humans; Mineralocorticoid Receptor

2012
[Rhythm control and rate control as therapy for patients with atrial fibrillation].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Feb-10, Volume: 95, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit

2006

Trials

17 trials available for spironolactone and Atrial Fibrillation

ArticleYear
Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: A single-center randomized controlled study.
    Clinical cardiology, 2021, Volume: 44, Issue:8

    Topics: Atrial Fibrillation; Catheter Ablation; Heart Atria; Humans; Pulmonary Veins; Recurrence; Spironolac

2021
Galectin-3 in patients with atrial fibrillation and restored sinus rhythm.
    Folia medica, 2021, Jun-30, Volume: 63, Issue:3

    Topics: Aged; Atrial Fibrillation; Biomarkers; Female; Fibrosis; Galectin 3; Gout; Humans; Kidney Diseases;

2021
Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy.
    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2022, Volume: 40

    Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Death; Dog Diseases; Dogs; Euthanasia, Animal

2022
Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction.
    European heart journal. Cardiovascular Imaging, 2017, Jul-01, Volume: 18, Issue:7

    Topics: Aged; Atrial Fibrillation; Comorbidity; Double-Blind Method; Echocardiography, Doppler; Female; Hear

2017
Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.
    The American journal of cardiology, 2017, 06-01, Volume: 119, Issue:11

    Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiograph

2017
Eplerenone might affect atrial fibrosis in patients with hypertension.
    Pacing and clinical electrophysiology : PACE, 2017, Volume: 40, Issue:10

    Topics: Aged; Atrial Fibrillation; Electrocardiography; Eplerenone; Female; Fibrosis; Heart Atria; Humans; H

2017
Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker.
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2018, Volume: 51, Issue:1

    Topics: Aged; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Double-Blind Method; Echoca

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Female; Heart Ar

2018
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    JACC. Heart failure, 2019, Volume: 7, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death;

2019
Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial.
    American heart journal, 2019, Volume: 214

    Topics: Adult; Aldosterone; Aortic Valve; Atrial Fibrillation; Coronary Artery Bypass; Double-Blind Method;

2019
Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:1

    Topics: Aged; Atrial Fibrillation; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male

2020
The role of spironolactone in the metabolism of serum type I collagen in elderly patients with atrial fibrillation.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:19

    Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Collagen Type I; Diuretics; Female; Follow

2014
IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.
    BMJ open, 2016, 10-05, Volume: 6, Issue:10

    Topics: Aged; Atrial Fibrillation; Diastole; Double-Blind Method; Exercise Test; Exercise Tolerance; Female;

2016
Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
    The American journal of cardiology, 2010, Dec-01, Volume: 106, Issue:11

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Bl

2010
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.
    Journal of the American College of Cardiology, 2012, May-01, Volume: 59, Issue:18

    Topics: Aged; Atrial Fibrillation; Disease Progression; Dose-Response Relationship, Drug; Electrocardiograph

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Blood Pressure; Cardiac Surgica

2012
Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session.
    Journal of the American College of Cardiology, 2002, Jul-03, Volume: 40, Issue:1

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Antihypertensive Agents; Atherect

2002

Other Studies

41 other studies available for spironolactone and Atrial Fibrillation

ArticleYear
Spironolactone of no benefit in people with AF and HFpEF.
    Drug and therapeutics bulletin, 2021, Volume: 59, Issue:12

    Topics: Atrial Fibrillation; Heart Failure; Humans; Spironolactone; Stroke Volume

2021
Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF.
    Journal of the American Heart Association, 2020, 09-15, Volume: 9, Issue:18

    Topics: Aldosterone; Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spi

2020
Do Mineralocorticoid Receptor Antagonists Suppress Atrial Fibrillation/Flutter?
    Journal of the American College of Cardiology, 2021, 07-13, Volume: 78, Issue:2

    Topics: Atrial Fibrillation; Atrial Flutter; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone

2021
Effects of Spironolactone on Hypoxia-Inducible Factor-1α in the Patients Receiving Coronary Artery Bypass Grafting.
    Journal of cardiovascular pharmacology, 2021, 07-01, Volume: 78, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Coronary Artery Bypass; Coronary St

2021
Interpretation of the ATHENA Trial-Caveats and Future Directions.
    JAMA cardiology, 2018, 01-01, Volume: 3, Issue:1

    Topics: Atrial Fibrillation; Heart Failure; Humans; Spironolactone

2018
Upstream Targets to Treat Atrial Fibrillation.
    Journal of the American College of Cardiology, 2017, 12-12, Volume: 70, Issue:23

    Topics: Atrial Fibrillation; Atrial Remodeling; Eplerenone; Heart Atria; Humans; Spironolactone

2017
Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.
    Journal of the American College of Cardiology, 2017, Dec-12, Volume: 70, Issue:23

    Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Cardiac Pacing, Artificial; Eplerenone; Fibrosis; M

2017
Medical Versus Surgical Treatment of Primary Aldosteronism.
    Hypertension (Dallas, Tex. : 1979), 2018, Volume: 71, Issue:4

    Topics: Adrenalectomy; Atrial Fibrillation; Humans; Hyperaldosteronism; Spironolactone

2018
Risk of renal dysfunction in an elderly patient with chronic heart failure.
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:10

    Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio

2016
Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Atrial Fibrillation; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Miner

2018
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
    Kardiologiia, 2013, Volume: 53, Issue:3

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C

2013
The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.
    The Journal of biological chemistry, 2014, Mar-07, Volume: 289, Issue:10

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Atrial Fibrillation; Connective Tissue Growth

2014
Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2015, Volume: 104, Issue:1

    Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Chi-Square Distribut

2015
[Internal medicine in the hospital setting].
    Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases

2015
Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy.
    International journal of cardiology, 2016, Jan-01, Volume: 202

    Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Databases, Factual; Diuretics; Female; Follow-Up Studi

2016
Increased aldosterone-dependent Kv1.5 recycling predisposes to pacing-induced atrial fibrillation in Kcne3-/- mice.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016, Volume: 30, Issue:7

    Topics: Adrenal Glands; Aldosterone; Animals; Atrial Fibrillation; Electrophysiological Phenomena; Gene Expr

2016
A beneficial effect of 3-year spironolactone therapy supplementing atenolol therapy on the remodeling of atria and ventricles in a patient with permanent atrial fibrillation.
    Internal and emergency medicine, 2009, Volume: 4, Issue:2

    Topics: Adult; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Heart Atria; Heart Ventricles; Humans;

2009
[Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation].
    Zhonghua xin xue guan bing za zhi, 2009, Volume: 37, Issue:7

    Topics: Aldosterone; Animals; Atrial Fibrillation; Atrial Function; Disease Models, Animal; Dogs; Male; Mine

2009
Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.
    British journal of pharmacology, 2010, Volume: 159, Issue:8

    Topics: Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Dogs; Female; Heart Atria;

2010
Agents with antialdosterone properties should be the preferred diuretics for reducing hypertension related atrial fibrillation.
    European journal of internal medicine, 2010, Volume: 21, Issue:1

    Topics: Antihypertensive Agents; Atrial Fibrillation; Diuretics; Eplerenone; Humans; Hypertension; Spironola

2010
Association between renin-angiotensin-aldosterone system blockers and postoperative atrial fibrillation in patients with mild and moderate left ventricular dysfunction.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2010, Volume: 10, Issue:2

    Topics: Adrenergic Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensi

2010
Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.
    British journal of pharmacology, 2010, Volume: 159, Issue:8

    Topics: Atrial Fibrillation; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone

2010
Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
    Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 382, Issue:4

    Topics: Animals; Atrial Fibrillation; Calcium Channels, L-Type; Cardiac Pacing, Artificial; Disease Models,

2010
Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:5

    Topics: Animals; Atrial Fibrillation; Cardiomegaly; Eplerenone; Fibrosis; Heart Atria; Hypertension; Male; M

2011
Effect of spironolactone on patients with atrial fibrillation and structural heart disease.
    Clinical cardiology, 2011, Volume: 34, Issue:7

    Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Elect

2011
Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2012, Volume: 29, Issue:5-6

    Topics: Action Potentials; Aldosterone; Animals; Atrial Fibrillation; Blood Pressure; Blotting, Western; Mal

2012
Combined hypotensive treatment with ≥ 3 hypotensive drugs in patients with recurrent atrial fibrillation and arterial hypertension ensures more effective arrhythmia control than using less drugs.
    Kardiologia polska, 2012, Volume: 70, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillat

2012
Precardiac surgery angiotensin-converting enzymes and mineralocorticoid blockers do not trump atrial fibrillation but possibly acute kidney injury: the value of a negative randomized study.
    Critical care medicine, 2012, Volume: 40, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Cardiac Surgical Procedures; Female;

2012
A therapeutic opportunity that needs to be optimized.
    American heart journal, 2012, Volume: 164, Issue:4

    Topics: Antihypertensive Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Atrial Fibrillation; Eplereno

2012
Global systolic load, left ventricular hypertrophy, and atrial fibrillation.
    American heart journal, 2012, Volume: 164, Issue:4

    Topics: Antihypertensive Agents; Aortic Valve Stenosis; Asymptomatic Diseases; Atrial Fibrillation; Eplereno

2012
Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation.
    The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7

    Topics: Atrial Fibrillation; Biomarkers; Catheter Ablation; Chi-Square Distribution; Combined Modality Thera

2013
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction.
    European heart journal, 2005, Volume: 26, Issue:20

    Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Atria; Heart Failure; Male; M

2005
Aldosterone antagonism and atrial fibrillation: time for clinical assessment?
    European heart journal, 2005, Volume: 26, Issue:20

    Topics: Animals; Atrial Fibrillation; Cardiomyopathy, Dilated; Fibrosis; Heart Failure; Mineralocorticoid Re

2005
Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation.
    BMJ (Clinical research ed.), 2006, Apr-22, Volume: 332, Issue:7547

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Black People;

2006
Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs.
    Chinese medical journal, 2008, Jan-05, Volume: 121, Issue:1

    Topics: Animals; Atrial Fibrillation; Cardiac Volume; Collagen; Dogs; Heart Atria; Heart Failure; Hemodynami

2008
[Correlation of digoxin levels in the myocardium, plasma and saliva in patients under chronic treatment].
    Archivos de farmacologia y toxicologia, 1981, Volume: 7, Issue:1

    Topics: Adult; Aged; Atrial Fibrillation; Diazepam; Digoxin; Drug Therapy, Combination; Female; Humans; Male

1981
A new interference in some digoxin assays: anti-murine heterophilic antibodies.
    Clinical pharmacology and therapeutics, 1996, Volume: 60, Issue:5

    Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardenolides; Digoxin; Diuretics; Drug Interactions; Dr

1996
[Pharma-clinics. How I treat...symptomatic heart failure].
    Revue medicale de Liege, 1999, Volume: 54, Issue:7

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Decision

1999
Paroxysmal atrial fibrillation with asystole and syncope: report of a case of sinus node dysfunction with hypokalemia and hypertension.
    Japanese circulation journal, 1976, Volume: 40, Issue:2

    Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Heart Arrest; Humans; Hypertension; Hypokalemia; Male; Mi

1976
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery.
    Scandinavian journal of thoracic and cardiovascular surgery, 1973, Volume: 7, Issue:1

    Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi

1973
Direct current cardioversion in digitalized patients with mitral valve disease.
    Archives of internal medicine, 1969, Volume: 123, Issue:2

    Topics: Adult; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardiac Complexes, Pr

1969